a condition that possibly impacts over 2 million patients worldwide but has no labelled drug," Cipla MD and Global CEO Umang Vohra said. Pulmatrix CEO Robert W Clarke said: "Cipla's expertise in ...

On acquisitions, the Cipla MD said, they would be interested in acquiring brands in its core areas in India, besides select capabilities in the United States, he said. The growth plans come even ...

While Torrent Pharma, a smaller rival, has emerged as a frontrunner, on the other side, Dr Reddy's Labs was reportedly approached by Bain Capital to make a joint bid for Cipla. The promoters ...

Another US-based PE titan, Bain Capital, was talking to Dr. Reddy’s Laboratories, the second-largest pharma major by sales, about joining hands to acquire Cipla. Hamied chose not to address the ...

New Delhi, Apr 2 () Pharma major Cipla on Thursday announced the successful completion of Phase-3 clinical study for generic fluticasone propionate and salmeterol inhalation powder indicated for ...

Mumbai-based generic drugmaker Cipla Ltd has hired a former executive at Dr Reddy’s Laboratories Ltd as its global general counsel to fill a post that had been lying vacant for almost a year, a person ...

Bino Pathiparampil, Head of Research, Elara Capital, says companies like Dr Reddy’s, Zydus, Cipla, Sun, can sustain a ...

Torrent Pharma is the most well-placed candidate to acquire the 33% promoter stake in India’s third largest pharma company CIPLA, edging out rival Dr Reddy’s Laboratories and private equity ...

a condition that possibly impacts over 2 million patients worldwide but has no labelled drug," Cipla MD and Global CEO Umang Vohra said. Pulmatrix CEO Robert W Clarke said: "Cipla's expertise in ...